Regulatory Approvals

FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer

By

Regulatory Approvals — FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer  OncLive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 26, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers

Regulatory Approvals

FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer

Regulatory Approvals

FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer

Financial News For All

Labor

Skydance Is Offering Employees Voluntary Buyouts Ahead of Layoffs, Adopts 5-Day-per-Week In-Office Policy

Labor

Microsoft makes new ‘voluntary exit’ offer to about a quarter of its workforce, including some execs

Labor

IKEA Teamsters Win Strike In Illinois

Labor

Corvallis, Oregon, city workers return to work after successful strike